Quantum leap to better and faster hits and leads

Search More x Find Better = Move Faster

Harness the power of quantum computing today

Get a head start on hard-to-find molecules

Start with a chemical universe out of reach by conventional screening

Explore a de novo combinatorial space or your choice of an on-demand chemical space as your starting point.

Apply to any protein target

Our quantum-aided solutions can be used to design a broad range of drug molecules, targeting PPI, trans-membranal, GPCRs, metallo-proteins, kinases, and any other protein targets.

Screen for all your objectives in a single run

Eliminate multiple iterations – identify high-quality candidates that are optimized for drug-likeness, synthetic accessibility, BBB permeability and other user-defined properties.

No training data required

Unlike AI solutions that hinge on available training data, our quantum-aided solutions use physics-based calculations with no need for parametrization—making it suitable for limitless drug targets.

Your goals. Your way.

Best-in-Class

Prioritizing similarity to template structure

First-in-Class

Prioritizing novelty

Library-Bound

Targeting your preferred rapid synthesis libraries

Scaffold-Hopping

Hold certain fragments constant while varying others

Your choice of deliverables to accelerate your discovery pipeline

In just 2 weeks

QuADD
Rapid

A hit library with 1000–5000 of your best-shot novel candidates

In just 90 days
QuADD
Select

A hit library with your best-shot novel candidates
+ A selection of the top 20–200 optimized leads

What our customers are saying

“Our collaboration with PolarisQB led to rapid identification of viable drug candidates, significantly accelerating our research timeline towards quality solutions for hard to tackle or neglected diseases affecting women’s health.”
Pek Lum, Ph.D., CEO, Auransa
“Using quantum computing and advanced AI technology with PolarisQB, we explored a chemical space that was previously undefined, leading to the discovery of novel molecules for our primary program of Optimizing the Aging and Longevity Molecular Process much faster than expected.”
Dr. Arthur Bollon, President and Co-Founder, Allosteric Bioscience
“This partnership represents the ultimate ambition for collaboration between biology and technology, where the full diversity of newly identified disease targets can be married to the most logical and rapid method of finding small molecule drugs.”
Chris Torrance, CEO, Phoremost
PolarisQB_Logo_IconOnly_FullColor

Can quantum computing help you find your next star molecule?